| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 6, Issue 11 1387-1394, Copyright © 1995 by American Association of Cancer Research
ARTICLES |
A D'Alessio, G De Vita, G Cali, L Nitsch, A Fusco, G Vecchio, G Santelli, M Santoro and V de Franciscis
Endocrinology and Experimental Oncology Center, Consiglio Nazionale delle Ricerche, Italy.
Expression of the RET proto-oncogene, a cell surface receptor for an as yet unknown ligand, is associated with tumors, tissues, and cell lines of neural crest origin. Accumulating evidence suggests that RET activity is involved in the process of neuronal differentiation. Moreover, induction of phenotypic differentiation of neuroblastoma cell lines is associated with the rapid accumulation of RET transcripts. To verify the role of RET in neuronal differentiation, we introduced into the human neuroblastoma cell line SK-N-BE four versions of the RET oncogene, activated by different mechanisms: RET/PTC1 and RET/PTC3, which are activated by rearrangement with heterologous genes; and two activated RET mutants, which carry the single amino acid substitution found associated to the inheritance of the multiple endocrine neoplasia type 2A (retMEN2A allele) and type2B (retMEN2B allele), respectively. We demonstrate that, after transfection with the RET oncogenes, SK-N-BE cells display a reduced growth rate and acquire a neurite-bearing phenotype accompanied by enhanced expression of the axonal growth-associated protein, GAP-43, and the high molecular weight neurofilament, NF200. These results indicate that, when activated, RET is able to cause growth inhibition and to promote neuronal differentiation of neuroblastoma cells.
This article has been cited by other articles:
![]() |
S. M. Myers and L. M. Mulligan The RET Receptor Is Linked to Stress Response Pathways Cancer Res., July 1, 2004; 64(13): 4453 - 4463. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Colucci-D'Amato, A. D'Alessio, D. Califano, G. Cali, C. Rizzo, L. Nitsch, G. Santelli, and V. de Franciscis Abrogation of Nerve Growth Factor-induced Terminal Differentiation by ret Oncogene Involves Perturbation of Nuclear Translocation of ERK J. Biol. Chem., June 16, 2000; 275(25): 19306 - 19314. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Le Hir, L. G. Colucci-DAmato, N. Charlet-Berguerand, P.-F. Plouin, X. Bertagna, Vittorio de Franciscis, and C. Thermes High Levels of Tyrosine Phosphorylated Proto-Ret in Sporadic Pheochromocytomas Cancer Res., March 1, 2000; 60(5): 1365 - 1370. [Abstract] [Full Text] |
||||
![]() |
R. M. Melillo, M. V. Barone, G. Lupoli, A. M. Cirafici, F. Carlomagno, R. Visconti, B. Matoskova, P. P. Di Fiore, G. Vecchio, A. Fusco, et al. Ret-mediated Mitogenesis Requires Src Kinase Activity Cancer Res., March 1, 1999; 59(5): 1120 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Califano, C. Rizzo, A. D'Alessio, G. L. Colucci-D'Amato, G. Cali, P. C. Bartoli, G. Santelli, G. Vecchio, and V. de Franciscis Signaling through Ras Is Essential for ret Oncogene-induced Cell Differentiation in PC12 Cells J. Biol. Chem., June 16, 2000; 275(25): 19297 - 19305. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |